COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC…
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE…
COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program…
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added…
SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the…
Doubles down on its commitment to connecting the world with the right doctors and advancing healthcare innovation and inclusionNEW YORK,…
Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study…
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective…
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option…